Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3025 SEK | -0.82% | +7.84% | -25.77% |
Mar. 26 | Transcript : Vivesto AB - Special Call | |
Mar. 07 | Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial | CI |
Sales 2021 | 28.87M 2.66M | Sales 2022 | 3.04M 280K | Capitalization | 234M 21.53M |
---|---|---|---|---|---|
Net income 2021 | -133M -12.27M | Net income 2022 | -357M -32.92M | EV / Sales 2021 | 37.7 x |
Net cash position 2021 | 86.84M 8.01M | Net cash position 2022 | 134M 12.39M | EV / Sales 2022 | 32.6 x |
P/E ratio 2021 |
-8.86
x | P/E ratio 2022 |
-0.6
x | Employees | 14 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 61.42% |
Latest transcript on Vivesto AB
1 day | -0.82% | ||
1 week | +7.84% | ||
Current month | +7.84% | ||
1 month | -4.57% | ||
3 months | -21.43% | ||
6 months | +44.05% | ||
Current year | -25.77% |
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 0.3025 | -0.82% | 185 572 |
24-05-06 | 0.305 | -0.33% | 156,330 |
24-05-03 | 0.306 | +4.26% | 733,556 |
24-05-02 | 0.2935 | +4.63% | 270,776 |
24-04-30 | 0.2805 | -1.23% | 280,714 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 06:19 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-25.77% | 15.19M | |
+31.52% | 690B | |
+25.05% | 546B | |
-5.21% | 358B | |
+17.02% | 323B | |
+5.01% | 287B | |
+14.06% | 235B | |
+5.31% | 199B | |
-9.98% | 195B | |
+3.98% | 161B |
- Stock Market
- Equities
- VIVE Stock